ONCO Share Price Performance
Recent ONCO News & Updates
No updates
Onco-Innovations Limited Key Details
Last Reported Earnings
Apr 30, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0012
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Onco-Innovations Limited Competitors
About ONCO
- Founded
- n/a
- Employees
- 1
- CEO
- WebsiteView website
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. Its lead product candidate is ONC010, a novel inhibitor of the deoxyribonucleic acid repair enzyme polynucleotide kinase 3'-phosphatase in a nanoparticle formulation based on the drug delivery technology. The company is headquartered in Calgary, Canada.
Canadian Market Performance
- 7 Days: 0.7%
- 3 Months: 10.9%
- 1 Year: 17.6%
- Year to Date: 10.6%
Over the last 7 days, the market has remained flat, although notably the Healthcare sector gained 4.2% in that time. Meanwhile, the market is actually up 18% over the past year. Looking forward, earnings are forecast to grow by 12% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading